Recent Advances in Priapism Management
The most significant recent advance is the 2022 AUA/SMSNA comprehensive guideline framework that mandates emergent evaluation to differentiate ischemic from non-ischemic priapism, with early urologic intervention for ischemic cases and a shift toward distal shunt procedures over proximal techniques, plus consideration of early penile prosthesis placement for prolonged ischemic priapism. 1
Critical Diagnostic Advances
Immediate Subtype Differentiation
All patients presenting with priapism require emergent evaluation to identify whether they have acute ischemic versus non-ischemic priapism 1. This distinction is now recognized as the single most important initial step, as it completely changes management urgency and approach.
Corporal blood gas analysis should be obtained at initial presentation as the primary diagnostic tool 2. The key values that define acute ischemic priapism are:
- PO2 <30 mm Hg
- PCO2 >60 mm Hg
- pH <7.25
These values contrast sharply with normal arterial blood (PO2 >90, PCO2 <40, pH 7.40) 2.
Role of Advanced Imaging
When corporal blood gas results are indeterminate, penile duplex Doppler ultrasound may be utilized to clarify the diagnosis 2. Emerging evidence suggests magnetic resonance imaging shows promise for better characterization, though it requires further validation before routine clinical integration 3.
Management Algorithm Advances
Acute Ischemic Priapism (The Emergency)
Time-dependent intervention is critical because untreated ischemic priapism leads to cavernous fibrosis and permanent erectile dysfunction 2. The structured stepwise approach has been refined:
First-Line Treatment
- Cavernosal aspiration of up to 500 ml of blood, with or without intracavernosal phenylephrine administration 3
- This represents the initial conservative approach that can preserve erectile function in most cases when performed early 4
Surgical Intervention Hierarchy
A major shift has occurred in surgical preferences:
- Distal shunt procedures have now surpassed proximal approaches (Quackels or Grayhack) as the preferred surgical technique 4
- Proximal shunts are no longer routinely performed 4
- A novel penoscrotal decompression technique has been described as an innovative surgical option 3, 4
- Novel surgical techniques including "tunneling" are now included in guideline recommendations 2
Early Prosthesis Consideration
For ischemic priapism persisting >36 hours, the majority of patients will develop erectile dysfunction 4. In these cases, early penile prosthesis placement with thorough patient counseling should be considered rather than continuing futile conservative measures 2, 4. This represents a paradigm shift from older approaches that delayed definitive treatment.
Non-Ischemic Priapism (Not an Emergency)
Non-ischemic priapism does not require urgent urologic intervention 1. Treatment must be individualized based on patient objectives, available resources, and clinician experience 1.
Conservative vs. Interventional Approach
- Primary treatment strategy remains conservative management 3
- When conservative measures fail, multiple super-selective embolization procedures are preferred over surgical ligation 4
- Early treatment with embolization is increasingly recommended to prevent fibrosis development in the distal corpora that can occur with long-standing non-ischemic priapism 4
Recurrent Ischemic Priapism (Stuttering Priapism)
The 2022 guidelines provide a refined definition: recurrent ischemic episodes with or without meeting the 4-hour criteria, but requiring confirmed penile ischemia 1.
Management requires:
- Treatment of acute episodes using the same algorithm as acute ischemic priapism
- Focus on future prevention of acute ischemic events necessitating surgical management 1
Sickle Cell Disease-Associated Priapism
Urologic relief of the erection should be the initial focus, with standard sickle cell assessment and interventions considered concurrent with urologic intervention, not sequential 1. This represents a shift from older approaches that prioritized hematologic management first.
Special Populations and Situations
Iatrogenic Priapism
Treatment protocols for prolonged iatrogenic erection (such as after intracavernosal injections) must be differentiated from protocols for true priapism 1. Recent data shows patients developing priapism after in-office intracavernosal injections are younger, have higher prevalence of mood disorders, behavioral disorders, and sickle cell disease 5. Proper screening and counseling is essential.
Risk Stratification
Patients at higher risk include those with:
- Sickle cell disease (6% prevalence in priapism after ICI vs <1% general population) 5
- Mood disorders (20% vs 14%) 5
- Behavioral disorders (7% vs 2%) 5
Emerging Technologies
Artificial Intelligence
AI models are being developed to predict the need for surgical intervention and improve diagnostic accuracy, though this remains investigational and not yet ready for clinical implementation 6.
Training Innovations
Given the rarity of priapism presentations, simulation-based training using moderate-fidelity task trainers has emerged as an important educational tool for emergency physicians and urologists 7. This addresses the reality that many physicians lack hands-on experience with these time-sensitive procedures.
Critical Pitfalls to Avoid
- Delaying corporal blood gas analysis - this is the definitive diagnostic test and should be performed immediately 2
- Treating non-ischemic priapism as an emergency - this leads to unnecessary interventions 1
- Continuing conservative measures beyond 36 hours in ischemic priapism - erectile dysfunction is nearly inevitable at this point, and early prosthesis should be discussed 4
- Performing proximal shunts - these have been abandoned in favor of distal techniques 4
- Prioritizing hematologic management over urologic intervention in sickle cell patients - these should occur concurrently 1